Published in Medical Letter on the CDC and FDA, January 31st, 2010
The T-Stat continuum sensor relies on broadband, multispectral visible and infrared illumination in order to obtain market-leading absolute tissue oximetry noninvasively in tissues such as the brain, gut, and breast. An FDA review process for marketing approval is underway, and Spectros anticipates marketing the Continuum sensor upon receipt of FDA marketing approval. Clinical studies of the Continuum sensor were initiated in 2008, with additional studies planned and in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA